Jun. 23 at 8:32 PM
$ARMP
received an additional
$2.5 million in non-dilutive funding from the U.S. Department of Defense, raising its total award to
$28.7 million to support Phase 3 readiness of its lead bacteriophage clinical candidate, AP-SA02.
https://prismmarketview.com/companies/armata-pharmaceuticals-inc/